Oxidative Stress and Inflammation as Predictors of Mortality and Cardiovascular Events in Hemodialysis Patients: The DREAM Cohort

Aim: Both oxidative stress and inflammation are involved in the pathogenesis of cardiovascular disease (CVD). The serum level of derivatives of reactive oxygen metabolites (d-ROMs) is a measure of the total amount of hydroperoxides serving as a marker of oxidative stress. We investigated whether d-ROMs could predict the clinical outcomes in hemodialysis patients and whether the associations of d-ROMs with the outcomes are independent of a marker of inflammation, C-reactive protein (CRP). Methods: This was a prospective cohort study in hemodialysis patients. The key exposures were the serum levels of d-ROMs and CRP. The outcome measures were all-cause mortality and new CVD events. Results: A total of 517 patients were analyzed. d-ROMs correlated positively with CRP. During follow-up for 5 years, 107 patients died, and 190 patients experienced new CVD events. In the Kaplan–Meier analyses, both higher d-ROMs and higher CRP levels predicted higher risks for mortality and CVD events. By Cox proportional-hazard regression analysis adjusted for potential confounders excluding CRP, d-ROMs exhibited a significant association with all-cause mortality, but this association was no longer significant after further adjustment for CRP. Using the same model, CRP exhibited a significant association with all-cause mortality, but this association was no longer significant after further adjustment for d-ROMs. When we analyzed new CVD events as the outcome, CRP was a significant predictor, whereas the level of d-ROMs was not. Conclusions: Although d-ROMs predicted mortality and CVD events in unadjusted models, the associations of d-ROMs with these outcomes were not independent of CRP. Oxidative stress and inflammation appear to share common causal pathways.

[1]  S. Yamagishi,et al.  Association of Hemoglobin A1c, 1,5-Anhydro-d-Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study , 2020, Diabetes Therapy.

[2]  H. Brenner,et al.  Association of Serum Markers of Oxidative Stress With Incident Major Cardiovascular Events, Cancer Incidence, and All-Cause Mortality in Type 2 Diabetes Patients: Pooled Results From Two Cohort Studies , 2019, Diabetes Care.

[3]  J. McMurray,et al.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. , 2019, The New England journal of medicine.

[4]  N. Yorioka,et al.  Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial , 2018, JAMA.

[5]  H. Brenner,et al.  Association of serum markers of oxidative stress with myocardial infarction and stroke: pooled results from four large European cohort studies , 2018, European Journal of Epidemiology.

[6]  S. Fukumoto,et al.  Altered Serum n-6 Polyunsaturated Fatty Acid Profile and Risks of Mortality and Cardiovascular Events in a Cohort of Hemodialysis Patients. , 2018, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[7]  M. Emoto,et al.  Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients , 2017, Journal of atherosclerosis and thrombosis.

[8]  L. Benítez-Bribiesca,et al.  Impact of Oxidative Stress in Premature Aging and Iron Overload in Hemodialysis Patients , 2016, Oxidative medicine and cellular longevity.

[9]  S. Fukuhara,et al.  Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation , 2016, Clinical and Experimental Nephrology.

[10]  C. Wanner,et al.  The heart and vascular system in dialysis , 2016, The Lancet.

[11]  H. Brenner,et al.  Evidence for the free radical/oxidative stress theory of ageing from the CHANCES consortium: a meta-analysis of individual participant data , 2015, BMC Medicine.

[12]  Wanchun Tang,et al.  Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition , 2015, Journal of the American Heart Association.

[13]  P. Stenvinkel,et al.  Oxidative DNA Damage and Mortality in Hemodialysis and Peritoneal Dialysis Patients , 2015, Peritoneal Dialysis International.

[14]  S. Fukumoto,et al.  Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  H. Arima,et al.  Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  S. Fukumoto,et al.  Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Kohno,et al.  Significance of measuring oxidative stress in lifestyle-related diseases from the viewpoint of correlation between d-ROMs and BAP in Japanese subjects , 2011, Hypertension Research.

[18]  H. Koyama,et al.  Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate , 2010, BMC nephrology.

[19]  P. G. Wells,et al.  Prostaglandin H synthase-1-catalyzed bioactivation of neurotransmitters, their precursors, and metabolites: oxidative DNA damage and electron spin resonance spectroscopy studies. , 2009, Chemical research in toxicology.

[20]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[21]  D. Tarng,et al.  GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. , 2009, Journal of the American Society of Nephrology : JASN.

[22]  D. Tarng,et al.  Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. , 2008, Journal of the American Society of Nephrology : JASN.

[23]  S. Hazen,et al.  Serum myeloperoxidase and mortality in maintenance hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  C. Boni,et al.  Elevated hydroperoxide levels as a prognostic predictor of mortality in a cohort of patients with cardiovascular disease. , 2006, International journal of cardiology.

[25]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[26]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[27]  F. Berrino,et al.  Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. , 2004, The International journal of biological markers.

[28]  T. Ikizler,et al.  Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. , 2004, Kidney international.

[29]  J. Morrow,et al.  Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. , 2004, Kidney international.

[30]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[31]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[32]  C. Wanner,et al.  Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  M. Emoto,et al.  Advanced atherosclerosis in predialysis patients with chronic renal failure. , 2002, Kidney international.

[34]  L. Sugherini,et al.  Plasma Total Antioxidant Capacity in Hemodialyzed Patients and Its Relationships to other Biomarkers of Oxidative Stress and Lipid Peroxidation , 2002, Clinical chemistry and laboratory medicine.

[35]  V. Fogliano,et al.  Use of N, N -dimethyl- p -phenylenediamine to Evaluate the Oxidative Status of Human Plasma , 2002, Free radical research.

[36]  M. Emoto,et al.  Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.

[37]  J. Blumberg,et al.  Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. , 2001, Kidney international.

[38]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[39]  A. Nicolaides,et al.  A simple test to monitor oxidative stress. , 1999, International angiology : a journal of the International Union of Angiology.

[40]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  P. Jungers,et al.  Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. , 1998, Journal of immunology.

[42]  H. Sies,et al.  Oxidative stress: oxidants and antioxidants , 1997, Experimental physiology.